IAVI’s Global Call to Access for Monoclonal Antibodies for COVID-19 and Other Diseases

Strengthening regulatory and policy frameworks to enable access to monoclonal antibodies in AfricaПодробнее

IAVI at 25Подробнее

IAVI Annual Report 2020Подробнее

IAVI 2014: Extraordinary AntibodiesПодробнее

IAVI’s Project for Sustainable Access to AntibodiesПодробнее

IAVI Annual Report 2022Подробнее

Challenges and opportunities on the access to future monoclonal antibodies for HIV preventionПодробнее

Why An HIV VaccineПодробнее

IAVI Annual Report 2021Подробнее

Monoclonal Antibodies: A Potential Treatment for #COVID19Подробнее

IAVI 2014: A Vaccine for Africa, with AfricaПодробнее

Monoclonal Antibodies for COVID-19 in Africa: Promise and PitfallsПодробнее

Vaccines and Monoclonal Antibodies - Shelly Karuna, MD, MPHПодробнее

Live Q&A: Monoclonal Antibodies Treatment for COVID-19Подробнее

What did we learn in IAVI G001?Подробнее

Equitable Access to Monoclonal Antibody Treatmentfor COVID-19Подробнее

Vaccines Security in Africa: Which Way Next?Подробнее

IAVI Announces First-in-Human Clinical Trial of Native-like HIV Envelope Vaccine CandidateПодробнее

Vaccine-Induced Seropositive (VISP)Подробнее